Ecolab stock (US2824031014): Analyst consensus points to 27% upside potential

Ecolab shares trade at $254.07 amid 'Moderate Buy' ratings from 21 analysts forecasting average target of $322.53, signaling 26.94% upside, per MarketBeat data as of 05/08/2026.

Ecolab Inc. shares closed at $254.07 on May 8, 2026, on the NYSE, according to MarketBeat as of 05/08/2026. Over the past 90 days, the stock saw 5 analyst upgrades and 1 downgrade, contributing to a 'Moderate Buy' consensus from 21 Wall Street firms. Price targets range from $285 to $352, with an average implying 26.94% upside from recent levels.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Ecolab Inc.
• Sector/industry: Chemicals / Water treatment and hygiene
• Headquarters/country: St. Paul, Minnesota, USA
• Core markets: Global healthcare, food, hospitality, and industrial sectors
• Key revenue drivers: Institutional cleaning, water technologies, and pest elimination
• Home exchange/listing venue: NYSE (ECL)
• Trading currency: USD

Ecolab: core business model

Ecolab provides water, hygiene, and infection prevention solutions worldwide. The company serves over 3.5 million customer locations across foodservice, healthcare, hospitality, and manufacturing industries. Its business model centers on delivering customized programs that combine chemistry, equipment, and digital tools to optimize resource use and sustainability.

Ecolab operates through three main segments: Global Institutional & Specialty, Global Industrial, and Global Healthcare. Revenue stems from product sales, services, and equipment rentals, with a focus on recurring contracts that ensure stable cash flows. The company reported quarterly revenue growth of 10.0% year-over-year in its latest period, alongside a net margin of 12.80% and return on equity of 22.64%, per recent filings cited on MarketBeat as of 05/10/2026.

Main revenue and product drivers for Ecolab

Ecolab's top revenue drivers include its Institutional division, which supplies cleaning and sanitizing solutions to restaurants and hotels, and the Industrial segment focused on water treatment for power plants and refineries. Key products like the CoolIT systems for data centers highlight recent innovation pushes, positioning Ecolab in high-growth areas amid rising demand for energy-efficient cooling, as noted in Finimize coverage.

The Healthcare segment contributes through infection control products, vital for US hospitals navigating post-pandemic hygiene standards. Overall, Ecolab derives significant exposure to the US market, where it generates a substantial portion of sales, making it relevant for American investors tracking industrial and healthcare supply chains.

Industry trends and competitive position

The water treatment and hygiene sector benefits from regulatory pressures on sustainability and water scarcity, trends favoring Ecolab's expertise. With a beta of approximately 0.70, Ecolab exhibits lower volatility than the broader market (22.23% vs. 32.43%), appealing to risk-averse US portfolios, per Finimize data.

Competitors include diverse chemical firms, but Ecolab's integrated service model and digital platforms like Ecolab Science Certified provide differentiation. Its one-year stock performance shows a -3.45% trend, underperforming some benchmarks but stable relative to peers.

Why Ecolab matters for US investors

Listed on the NYSE, Ecolab offers US investors direct access to a leader in essential services tied to the domestic economy's industrial and healthcare segments. Exposure to data center growth via deals like CoolIT aligns with booming US tech infrastructure spending.

Conclusion

Ecolab maintains a solid position in hygiene and water solutions, with recent analyst upgrades supporting a positive outlook amid stable financial metrics. Shares reflect modest near-term pressure but benefit from defensive qualities and growth in data centers. US investors may note its NYSE listing and economic ties as key factors in broader portfolio considerations.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.